Pure Global: U.S. FDA's Cyber War, Beyond the SBOM.

The U.S. FDA has just released crucial new draft guidance on medical device cybersecurity, fundamentally changing the requirements for market approval. This isn't just a recommendation; it's a new reality for MedTech manufacturers, directly linked to new federal laws that give the agency power to reject submissions on cybersecurity grounds alone. This episode breaks down what the "Refuse to Accept" policy means for your product pipeline. We explore the mandatory inclusion of a Software Bill of Materials (SBOM) and the shift towards a "total product lifecycle" approach to security, moving it from a final-stage check to a core design principle. Case Study: A mid-sized company developing a revolutionary wearable cardiac monitor is ready for its 510(k) submission. However, their software team used several open-source libraries without maintaining a formal SBOM. Under the new guidance, their submission is immediately rejected by the FDA, delaying market entry by nine months and costing millions in lost revenue and remediation. Their lack of a proactive cybersecurity plan became their biggest barrier to success. What You'll Learn: - What exactly is the FDA's new "Refuse to Accept" policy for cybersecurity? - How does the mandatory Software Bill of Materials (SBOM) impact legacy and new devices? - Why is a "total product lifecycle" approach now essential for your regulatory strategy? - What are the three biggest vulnerabilities the FDA is looking for in your submission? - How do you create a post-market surveillance plan that satisfies the new legal requirements? - Can this new regulatory hurdle actually become a competitive advantage for your company? - What specific documentation is now required to prove your device is cyber-resilient? For more information, contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.